Tag: Oliver Colvile

The below Parliamentary question was asked by Oliver Colvile on 2015-01-14.

To ask the Secretary of State for Transport, what plans his Department has to increase capacity on the railway between Exeter and Plymouth.

Claire Perry

Future rail proposals are being developed with local stakeholders the department and Network Rail, this group will be deliver a local plan for rail investment covering the next 10-20 years. The first step in this process is a meeting of interested parties which is being organised by the South West Peninsular Group, and is due to take place early February. This meeting will work through what is required to provide the South West with greater accessibility and to examine wider issues surrounding connectivity to and within the South West Peninsula.

The below Parliamentary question was asked by Oliver Colvile on 2015-02-12.

To ask the Secretary of State for Health, pursuant to the Answer of 3 July 2014, Official Report, column 710W, on pharmacy, what progress his Department has made on the introduction of data-sharing between GPs and pharmacists.

Dr Daniel Poulter

The Proof of Concept (POC) project is making good progress. The project has completed the implementation stage of providing Summary Care Record (SCR) access for community pharmacies.

By the end of 2014, 135 pharmacies across all five areas (West Yorkshire, Sheffield, Northamptonshire, Derbyshire and Somerset), have been enabled to have access to the SCR. The pharmacies involved include independent pharmacies, national multiple providers, and representatives from the major supermarkets. Over 1,300 patient SCRs have been accessed to date to support direct patient care.

The POC project team are now working on the findings and associated recommendations. Initial analysis is promising and the final report is due in the coming months.

The below Parliamentary question was asked by Oliver Colvile on 2015-02-11.

To ask the Secretary of State for Communities and Local Government, what steps his Department is taking to better enforce building regulation inspections to ensure quality housing builds.

Stephen Williams

The duty to comply with the requirements of the Building Regulations lies on the person carrying out the building work. The duty of the building control bodies, local authorities and approved inspectors, is to take all reasonable steps to satisfy themselves that the requirements have been satisfied. Where they have not been complied with a compliance certificate should not be given. It is also possible for building control bodies to take formal enforcement action in the courts against builders for non-compliance where they consider this would be justified. Issues relating to warranties which may be provided for new homes are matters for the relevant warranty body.

The below Parliamentary question was asked by Oliver Colvile on 2015-02-11.

To ask the Secretary of State for Health, what plans his Department has to review the regulatory framework for the dental profession.

Dr Daniel Poulter

The Law Commissions’ completed a review of the regulation of all health and social care professionals including dentists and reported in April 2014. They made 125 recommendations to improve the legislative framework and we published the Government response on 29 January 2015, accepting the vast majority of these recommendations.

The Government remains committed to legislate on this important issue when parliamentary time allows and are working closely with the regulatory bodies and the Professional Standards Authority to build on the important work the Law Commissions have done.

In the meantime we are taking forward a section 60 Order to amend the Dentists Act 1984 to make changes to the General Dental Council’s (GDC’s) investigation stage fitness to practise processes. A consultation has recently been undertaken on these measures which will be introduced subject to Parliamentary approval. It is expected the provisions should lead to the swifter resolution of complaints, as ultimately they will improve the efficiency of the GDC’s fitness to practise processes, whilst also enhancing patient protection and public confidence in dental regulation.

The below Parliamentary question was asked by Oliver Colvile on 2014-04-30.

To ask the Secretary of State for Health, if his Department will put restrictions in place to prevent the promotion of e-cigarettes to people under the age of 16 years.

Jane Ellison

The revised Tobacco Products Directive (Directive 2014/40/EU) will prohibit the advertising of e-cigarettes marketed as consumer electronic products where there is a cross-border dimension, for example television, radio, newspapers and magazines. The Department will consult on the transposition of the Directive into United Kingdom law and seek views on the need for domestic provisions on advertising.

It was not possible to achieve age of sale controls through the revised Directive so the Government has already moved quickly to take regulation-making powers for Ministers in England and Wales to prohibit the sale of e-cigarettes to under-18s, through the Children and Families Act. In England, we plan to bring this new law into effect within the current Parliament.

The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

To ask the Secretary of State for Business, Innovation and Skills, what specialist one-to-one study skills support will be available for students with specific learning difficulties following the review of the disabled students allowance; and who will provide that support.

Mr David Willetts

Discussions are underway with stakeholders, including those who specialise in supporting students with Specific Learning Difficulties. This will help determine how specialist one-to-one support will be delivered in the future and where the responsibility for funding such support will fall.

I will not make a final decision on this matter until I have considered the necessary Equality Analysis, which is in preparation, and will take account of any relevant evidence provided by stakeholders.

The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.

Jane Ellison

The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

To ask the Minister for the Cabinet Office, how many people died from prostate cancer in (a) Plymouth, Sutton and Devonport constituency and (b) England in each of the last five years.

Mr Nick Hurd

The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.

The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.

Jane Ellison

The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.

Jane Ellison

The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.